Pemetrexed interactions
Full monograph for PemetrexedCheck it against another medicine
Medicines
373 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Thalidomide | Major | Synergy | Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism… | 20 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| AcyclovirInjectionOphthalmicOral | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Adefovir Dipivoxil | Moderate | Excretion | Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney… | 1 sources — open the full entry |
| Allopurinol | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Amikacin | Moderate | Excretion | Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney… | 1 sources — open the full entry |
| Amoxicillin + Clavulanic Acid | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Amoxicillin Trihydrate | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Amphotericin B | Moderate | Excretion | Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney… | 1 sources — open the full entry |
| Ampicillin Sodium | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Aspirin | Moderate | Excretion | INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been… | 94 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Excretion | INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been… | 94 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Aztreonam | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Bacitracin Zinc + Polymyxin B Sulfate | Moderate | Excretion | Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney…2 documented mechanisms | 1 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Bendamustine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Benzathine Benzylpenicillin | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Moderate | Synergy | Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described… | 94 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Excretion | Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney… | 1 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Moderate | Excretion | Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney… | 1 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Synergy | Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described… | 94 sources — open the full entry |
| Bleomycin Sulfate | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Bromfenac Sodium | Moderate | Excretion | INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been… | 94 sources — open the full entry |
| Carboplatin | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Cefaclor Monohydrate | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefadroxil Monohydrate | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefazolin Sodium | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefdinir | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefditoren | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefixime Trihydrate | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefoperazone Sodium | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefotaxime | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefpodoxime Proxetil | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefpodoxime Proxetil + Clavulanic Acid | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefuroxime Axetil | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Cefuroxime Axetil + Clavulanic Acid | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
This source documents no food, condition or duplication entries for Pemetrexed.